The most frequent cause of infectious disease-related mortality globally is tuberculosis (TB), a multisystemic disease with a wide range of presentations and symptoms. Around 12% of extrapulmonary TB cases and 1–3% of all TB cases are caused by abdominal TB. The issue of antituberculosis drug-induced liver injury (ATLI), which has long been a challenge in the management of TB infection, is one of increased significance. The major steps to reduce the occurrence of ATLI are to identify the possible risk factors of hepatotoxicity and to provide an appropriate weight-based anti-tuberculosis treatment (ATT). Dosage adjustment in the intensive phase helps overcome the complications of liver injury associated with these drugs. Withdrawal of the drugs followed by reintroduction in a weight based manner, once the LFT is normal, helps achieve tolerance to the drugs.

Bincy Charley has completed her doctor of pharmacy degree from Kerala University of Health Sciences and has 2 years of experience as clinical pharmacist in a mission hospital in Kerala.